How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
